# Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases

> **NCT06471465** · PHASE3 · RECRUITING · sponsor: **Institut Cancerologie de l'Ouest** · enrollment: 84 (estimated)

## Conditions studied

- Radionecrosis of Brain
- Brain Metastases

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Placebo
- **DRUG:** Prednisolone

## Key facts

- **NCT ID:** NCT06471465
- **Lead sponsor:** Institut Cancerologie de l'Ouest
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-29
- **Primary completion:** 2028-08
- **Final completion:** 2030-08
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2025-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06471465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06471465, "Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06471465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*